Research Analysts Offer Predictions for 89BIO Q3 Earnings

89BIO (NASDAQ:ETNB) – Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for 89BIO in a note issued to investors on Thursday, September 4th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.50) for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for 89BIO’s current full-year earnings is ($3.19) per share. HC Wainwright also issued estimates for 89BIO’s Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.22) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.31) EPS, FY2027 earnings at ($2.03) EPS, FY2028 earnings at ($1.55) EPS and FY2029 earnings at ($0.35) EPS.

89BIO (NASDAQ:ETNB) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.22). During the same period in the previous year, the company posted ($0.48) earnings per share.

ETNB has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of 89BIO in a research note on Saturday, August 30th. Bank of America cut their target price on 89BIO from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Monday, August 25th. Finally, Royal Bank Of Canada cut their target price on 89BIO from $12.00 to $11.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $28.00.

89BIO Stock Performance

ETNB stock opened at $8.87 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 15.19 and a current ratio of 15.19. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -2.46 and a beta of 1.27. 89BIO has a 1 year low of $4.16 and a 1 year high of $11.84. The stock’s fifty day moving average is $9.64 and its two-hundred day moving average is $8.77.

Insider Activity at 89BIO

In other news, insider Quoc Le-Nguyen sold 10,461 shares of the firm’s stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $11.02, for a total transaction of $115,280.22. Following the transaction, the insider directly owned 309,364 shares of the company’s stock, valued at approximately $3,409,191.28. This trade represents a 3.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. grew its holdings in 89BIO by 25.9% during the second quarter. Osaic Holdings Inc. now owns 6,463 shares of the company’s stock worth $63,000 after acquiring an additional 1,330 shares during the period. Tower Research Capital LLC TRC increased its stake in 89BIO by 338.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 14,066 shares of the company’s stock worth $138,000 after purchasing an additional 10,859 shares in the last quarter. Holocene Advisors LP purchased a new position in 89BIO in the 2nd quarter worth about $30,102,000. Brevan Howard Capital Management LP purchased a new position in 89BIO in the 2nd quarter worth about $451,000. Finally, Bank of America Corp DE increased its stake in 89BIO by 59.9% in the 2nd quarter. Bank of America Corp DE now owns 1,249,954 shares of the company’s stock worth $12,275,000 after purchasing an additional 468,002 shares in the last quarter.

About 89BIO

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.